# Study of Telaprevir in Subjects With Hepatic Impairment

> **NCT00509210** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated**

## Conditions studied

- Hepatic Insufficiency

## Interventions

- **DRUG:** telaprevir (VX-950)

## Key facts

- **NCT ID:** NCT00509210
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** — (—)
- **Last updated:** 2008-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00509210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00509210, "Study of Telaprevir in Subjects With Hepatic Impairment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00509210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*